Check Claims Before You Publish

Key metrics (sourced)

• Author bibliometrics reported: h-index ≈ 11–12; total citations ≈ 399–510; works count 46–81 across different databases (Scopus/semantic records vs OpenAlex) — reflected in regionally important virology publications Integrase A6 susceptibility (Viruses 2020)
• Regional surveillance & translational focus: multiple co-authored papers analyzing HIV drug resistance, molecular epidemiology and national databases (PLOS ONE 2022; Viruses 2023) EECA PDR prevalence (PLOS ONE 2022) Russian national DR analysis (Viruses 2023)

Publication trend (counts by year from OpenAlex-like summary)

Top topics & strengths (evidence)

• Domain expertise: HIV molecular epidemiology, antiretroviral drug resistance, sequencing methodology and national/regional surveillance datasets — multiple papers analyze subtypes, integrase features, and PDR prevalence Integrase A6 susceptibility (Viruses 2020)
• Translational surveillance: co-authorship on multi-centre/regional analyses that inform public-health action thresholds and testing strategy rather than molecular mechanism alone EECA PDR prevalence (PLOS ONE 2022)
• Methods & data resources: participation in database-building / next-generation sequencing sensitivity / detection-methods papers that underpin surveillance capacity (e.g., national RHIVDB, NGS minority detection assessments) Russian national DR analysis (Viruses 2023)

Critical appraisal — methodological & evidence strengths

1. Strengths: consistent, domain-focused publication record; papers that combine molecular sequence data with public-health interpretation; open-access publications increasing transparency and reuse (several MDPI/PLoS ONE outputs).
2. Potential limitations / blindspots: many outputs are applied/surveillance-focused (valuable) but fewer highly-cited, mechanistic, or basic-science breakthroughs; variation in author position (first/last/middle) suggests collaborative role sometimes rather than sole senior leadership; some publications in regional journals with limited global visibility which lowers citation counts even if local impact is high.
3. Data quality considerations: surveillance and database analyses depend on sampling representativeness, sequencing depth and standardization; conclusions about prevalence/drifts should be weighed against sampling bias and temporal changes in ART coverage (papers themselves note surveillance limitations) EECA PDR prevalence (PLOS ONE 2022)

Concrete, evidence-linked recommendations to strengthen scientific profile

• Increase lead-author mechanistic or methods papers with thorough experimental design and publicly available raw datasets to raise citation impact and reproducibility.
• Publish standardized, reproducible analysis pipelines (code + raw sequence access) for national database studies to reduce reproducibility concerns and increase reuse.
• Pursue cross-disciplinary collaborations (e.g., with structural virology or therapeutic modelling groups) to translate surveillance findings into mechanistic insight that attracts broader citations.

What would change this appraisal?

Stronger evidence that would raise the scientific-score: (a) more first/last-author high-impact mechanistic papers with rigorous experimental validation; (b) publicly archived raw sequencing datasets with clear metadata; (c) independent external validation of predictive tools described in computational-methods papers. Conversely, discovery of undisclosed conflicts of interest or data-quality problems would lower confidence.